Mid-Morning Market Update: Markets Mixed; Ingersoll Rand Profit Misses Views - California Resources (NYSE

Following the market opening Tuesday, the Dow traded up 0.10% to 24,245.68 while the NASDAQ fell 0.17% to 9,177.10. The S&P also fell, dropping 0.23% to 2,923.65.

The U.S. is the new epicenter of the coronavirus pandemic with the highest number of cases and deaths around the world. U.S. reported a total of 1,347,930 coronavirus cases with around 80,680 deaths. Spain confirmed a total of over 227,430 coronavirus cases with 26,740 deaths, while Russia reported a total of at least 232,240 confirmed cases and 2,115 deaths. In total, there were at least 4,194,320 cases of COVID-19 worldwide with over 286,610 deaths, according to data compiled by Johns Hopkins University.

Leading and Lagging Sectors

Materials shares climbed by 0.9% on Tuesday. Meanwhile, top gainers in the sector included Vedanta Limited (NYSE:VEDL), up 21%, and Ferro Corporation (NYSE:FOE), up 10%.

In trading on Tuesday, real estate shares fell 2.1%.

Top Headline

Ingersoll Rand Inc. (NYSE:IR) reported weaker-than-expected earnings for its first quarter on Tuesday.

Ingersoll Rand posted quarterly adjusted earnings of $0.25 per share, missing analysts’ estimates of $0.27 per share. The company’s adjusted sales came in at $1.30 billion, exceeding the consensus view of $1.24 billion.

Equities Trading UP

Novavax, Inc. (NASDAQ:NVAX) shares shot up 61% to $39.49 after the company reported better-than-expected Q1 EPS and sales results. The company also announced it will receive up to $388 million in funding from CEPI for COVID-19 (coronavirus) vaccine development and manufacturing.

Shares of Rand Capital Corporation (NASDAQ:RAND) got a boost, shooting 60% to $2.19. Rand Capital shares climbed 8% on Monday after the company reported Q1 results.

Gamida Cell Ltd. (NASDAQ:GMDA) shares were also up, gaining 38% to $6.25 after the company reported positive topline data from Phase 3 clinical study of Omidubicel in patients with high-risk hematologic malignancies.

Equities Trading DOWN

Genfit SA (NASDAQ:GNFT) shares tumbled 65% to $7.70 after the company said interim analysis of the RESOLVE-IT Phase 3 trial that evaluated once-daily, 120mg of elafibranor in adults with NASH did not meet the redefined primary endpoint of NASH resolution without worsening of fibrosis in the ITT population of 1,070 patients. The study also did not achieve statistical significance in the key secondary endpoints, including fibrosis improvement of at least one stage and changes in metabolic parameters.

Shares of Advanced Emissions Solutions, Inc. (NASDAQ:ADES) were down 30% to $5.39 after reporting Q1 results. Advanced Emissions Solutions posted a Q1 loss of $0.11 per share.

California Resources Corporation (NYSE:CRC) was down, falling 29% to $1.7347.

Commodities

In commodity news, oil traded up 5.3% to $25.42, while gold traded up 0.6% to $1,707.80.

Silver traded up 0.5% Tuesday to $15.76, while copper fell 0.3% to $2.374.

Euro zone

European shares were higher today. The eurozone’s STOXX 600 rose 0.4%, the Spanish Ibex Index rose 1.1%, while Italy’s FTSE MIB Index rose 1.1%. Meanwhile, the German DAX gained 0.3%, and the French CAC 40 fell 0.2% while UK shares rose 1%.

Economics

The NFIB small business optimism index declined 5.5 points to a reading of 90.9 in April.

US annual inflation rate fell to 0.3% in April, versus 1.5% in March.

The Johnson Redbook Retail Sales Index fell 1.5% during the first week of May versus April.

Federal Reserve Bank of Philadelphia President Patrick Harker is set to speak at 12:00 p.m. ET.

The Treasury is set to auction 10-year notes at 1:00 p.m. ET.

The U.S. Treasury budget report for April will be released at 2:00 p.m. ET.

Federal Reserve Bank of Cleveland President Loretta Mester will speak at 5:00 p.m. ET.

CRCCalifornia Resources Corp